Activity Overview
In part I, faculty experts Jonathan Barratt, PhD, FRCP; and
Richard Lafayette, MD; discuss the current standard of care for the treatment
of IgAN, highlighting information from the most recent Kidney Disease:
Improving Global Outcomes guidelines.
Target Audience
This educational activity is directed toward nephrologists, nephrology nurses, nurse practitioners, physician assistants, registered nurses, and other health care practitioners involved in the care of patients with IgAN.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review pathophysiological mechanisms of IgAN
- Analyze recent efficacy and safety trial data on new and emerging treatments for IgAN
- Design individualized treatment plans for patients with IgAN
Professor Jonathan Barratt, PhD, FRCP
The Mayer Professor of Renal Medicine
Department of Cardiovascular Sciences
University of Leicester
Leicester, UK
Disclosures: Advisor, Consultant, Speaker, Honorarium Recipient: Alnylam, Argenx, Astellas, BioCryst, Calliditas, Chinook, Dimerix, Galapagos, Novartis, Omeros, Travere Therapeutics, Vera Therapeutics, Visterra; Grant/Research Funding: Argenx, Calliditas, Chinook, Galapagos, GlaxoSmithKline, Novartis, Omeros, Travere Therapeutics, Visterra
Richard Lafayette, MD
Professor of Medicine (Nephrology)
Stanford University Medical Center Director
Stanford Glomerular Disease Center
Stanford, CA
Disclosures: Advisor, Consultant, Fee for Service Recipient: Amgen, Alexion, Biogen, Biohaven, Calliditas, Dimerix, Otsuka, Takeda, Travere, Vera, Vertex Grant/Research Funding: Alexion, Biogen, Biohaven, Calliditas, Dimerix, Otsuka, Takeda, Travere, Vera, Vertex, NIH, Roche
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Additional Disclaimers
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity
may have used AI-assisted tools to support educational development. All content
was reviewed and approved by qualified faculty or planners. The accredited
provider retains full responsibility for accuracy, balance, and independence.